| 8.30 – 8.50 |
Registration and coffee/tea |
| |
|
| 8.50 –
9.00 |
Opening Dr. Arjan W. Griffioen (Amsterdam, The Netherlands) |
| |
|
| Session
1 |
|
| 9.00 –
9.40 |
Dr. Henk M.W. Verheul (Amsterdam, The Netherlands) |
| |
Individualized cancer
therapy |
| 9.40 – 10.20 |
Dr. Roberto Pili (Baltimore, USA) |
| |
Therapeutic strategies
to overcome resistance to anti-VEGF therapies in renal cell carcinoma |
| 10.20 – 11.00 |
Dr. Lee
Ellis (Houston, USA) |
| |
Mechanisms of action of
anti-VEGF therapy within the tumor microenvironment |
| |
|
| 11.00 – 11.30 |
Coffee/tea break |
| |
|
| Session 2 |
|
| 11.30 – 12.10 |
Dr. Adriana Albini (Milano, Italy) |
| |
Inflammatory angiogenesis: a target for therapy and prevention |
| 12.10 – 12.50 |
Dr.
Michael Klagsbrun (Boston, USA) |
| |
Mediators of axon
guidance inhibit tumor angiogenesis and progression |
| |
|
| 12.50 – 13.30 |
Lunch break |
| |
|
| Session 3 |
|
| 13.30 – 14.10 |
Dr. Stefan Schulte-Merker (Utrecht, The
Netherlands) |
| |
From
zebrafish development to the human clinic – the role of CCbe1
|
| 14.10 – 14.40 |
Dr. Takayuki Asahara (Kobe, Japan) |
| |
Endothelial progenitor cells
for organogenesis |
| |
|
| 14.40 – 14.45 |
Closing |
